Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast11 neoadjuvant T-DXd in high-risk HER2-positive early breast cancer
2021-000603-21Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Pathological complete response. Started Oct 2021; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-000603-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000603-21.